Yupelri

Active Ingredient(s): Revefenacin
FDA Approved: * November 9, 2018
Pharm Company: * THERAVANCE BIOPHARMA
Category: Lungs (Pulmonary)

Chronic obstructive pulmonary disease (COPD) is a type of progressive lung disease characterized by long-term respiratory symptoms and airflow limitation. The main symptoms include shortness of breath and a cough, which may or may not produce mucus. COPD progressively worsens, with everyday activities such as walking or dressing becoming difficult. While COPD is incurable, it is preventable and treatable. The two most common conditions of COPD are emphysema and chronic bronchitis and they hav... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Yupelri 175 ug/3ml Respiratory (Inhalation) Solution
NDC: 49502-806
Labeler:
Mylan Specialty L.p.